Company Overview of Adagio Pharmaceuticals Ltd.
Adagio Pharmaceuticals Ltd. owns and operates intellectual property relating to APL-130277, a reformulation of an approved Parkinson's drug. The company is based in Oakville, Canada. As of December 22, 2011, Adagio Pharmaceuticals Ltd. operates as a subsidiary of Cynapsus Therapeutics Inc.
1302 Kestell Boulevard
Oakville, ON L6H 0B9
Key Executives for Adagio Pharmaceuticals Ltd.
Adagio Pharmaceuticals Ltd. does not have any Key Executives recorded.
Similar Private Companies By Industry
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
|ABcann Medicinals Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Adagio Pharmaceuticals Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.